- Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030
- Enables manufacturing of medicines across company’s main therapeutic areas in one geographic location
- Marks latest milestone in company’s previously announced $23 billion investment in US infrastructure
East Hanover, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with end-to-end manufacturing capabilities. The strategic investment is a major step to ensure all key Novartis medicines for US patients are manufactured in the US and delivered to patients across the country at scale.
This announcement is part of Novartis’ $23 billion investment in US-based infrastructure over the next five years, designed to increase manufacturing capacity and enable 100% of the company’s key medicines to be produced end-to-end in the US.
As part of this flagship hub in North Carolina, Novartis will:
- Build a new site in Durham with the construction of two new facilities dedicated to manufacturing biologics and sterile packaging
- Build a new site in Morrisville with one facility for the production of solid dosage tablets and capsules, including packaging
- Expand the scope of its existing Durham facility with the added capability to support sterile filling of biologics into syringes and vials
The company is on track to produce all its advanced technologies in the US with:
- Cell and gene therapies manufactured in Morris Plains, NJ, and Durham, NC
- Radioligand therapies manufactured coast-to-coast at facilities in Millburn, NJ, Indianapolis, IN, and Carlsbad, CA, and two new sites planned in Florida and Texas
- xRNA therapies to be manufactured at a new facility whose location will be announced in the coming months
Currently, Novartis produces innovative, life-changing gene therapies in Durham. Together, the new and existing facilities will create a single hub, expanding capabilities to produce medicines across the company’s main therapeutic areas: oncology, immunology, neuroscience, and cardiovascular, renal and metabolic. The proximity of the facilities will allow teams and production processes to work in tandem – from manufacturing active ingredients to final packaging – and create efficiencies in its manufacturing…